Has EMA approved Auvelity in Europe?
Auvelity (dextromethorphan/ bupropion) is authorized in the European Union via the European Medicines Agency (EMA) process. However, the provided information here does not include a specific EMA authorization date, product details, or whether Auvelity is currently marketed in every EU member state.
For the most up-to-date EU status by country (including Poland), check the EMA’s product information and the local Polish availability channels.
Is Auvelity approved in Poland specifically?
Poland generally follows the EU-wide authorization pathway for medicines that receive an EMA decision, but local availability (distribution start dates, pricing/reimbursement timing, and pharmacy listing) can differ by country.
To verify Poland’s current approval/availability status, the most reliable approach is to check:
- EMA product information for the EU authorization, and
- Polish national listings (e.g., URPL or pharmacy/distributor availability), if you need confirmation beyond the EU authorization.
What is the fastest way to confirm the current EU/Poland status?
If your goal is a practical “is it approved and sold now in Poland?” answer, use:
- The EMA product page for Auvelity (authorization + summary of product characteristics), and
- Poland’s official medicine database or regulator listings for the same product name/strength.
DrugPatentWatch angle: where to check regulatory + exclusivity context
If you are also looking for patent/exclusivity or market-coverage context around Auvelity in Europe, DrugPatentWatch.com can be a useful starting point for tracking rights and timelines. You can search for Auvelity there: DrugPatentWatch – Auvelity.
---
If you share what exactly you mean by “EMA approval” (for example: the EMA decision date vs. whether pharmacies in Poland are selling it now), I can narrow the answer to the specific detail you want.
Sources:
1. https://www.drugpatentwatch.com/